Bortezomib for Multiple Myeloma Can Cause Reactivation of Viruses

Georg Härter

REFERENCE:47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 2007
GEORG HÄRTER, University Hospital, Ulm
For patients with multiple myeloma being treated with the proteasome inhibitor bortezomib, doctor’s should be wary of viral reactivation – and they should give antiviral prophylaxis in all cases. This finding was unveiled at ICAAC by Georg Härter from the University Hospital in Ulm, and he shared his data with Derek Thorne.